You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Erisyon will use its single-molecule protein sequencing technology to detect and validate biomarkers for early detection of Parkinson's disease.
Illumina will sequence 35,000 whole genomes for the Genetics of Mortality in Critical Care (GenOMICC) study and will provide an in-kind contribution.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The grants were awarded as part of Australia's Genomics Health Futures Mission, which was launched in 2018 as part of a broader health research initiative.
The Boston Globe reports Harvard University is paying $1.4 million to settle a claim that a former professor there overcharged work to US federal grants.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
With the help of Bionano Genomics, Genoox, Rescale, and Amazon, the investigators aim to study 1,000 patients with SARS-CoV-2 to better understand the disease.
The consortium, which spans more than a dozen UK cities, will sequence patient samples to understand the spread and evolution of the novel coronavirus.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.